Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on rhGM-CSF. (2010) NMR spectroscopy can obtain information on higher order structure of biopharmaceutical products.
(2010) Assessment of the effects of pH, formulation and deformulation on the conformation of interferon alpha-2 by NMR. Panjwani N, Hodgson DJ, Sauvé S, Aubin Y. (2012) Interactions between the conserved hydrophobic region of the prion protein and dodecylphosphocholine micelles. (2012) Evaluation of a candidate International Standard for Meningococcal Group C polysaccharide. Vipond C, Mulloy B, Rigsby P, Burkin K, Bolgiano B, MenC IS Working Group. (2012) Backbone and side chain (1)H, (13)C and (15)N resonance assignments of the catalytic domain of diphtheria toxin. (2013) A single GalNAc residue on Thr-106 modifies the dynamics and the structure of interferon alpha-2a around the glycosylation site. Ghasriani H, Belcourt PJ, Sauvé S, Hodgson DJ, Brochu D, Gilbert M, Aubin Y. Smith DGS, Gingras G, Aubin Y, Cyr TD (2016) Design and Expression of a QconCAT Protein to Validate Hi3 Protein Quantification of Influenza Vaccine Antigens, Journal of Proteomics 146: 133-40. Hodgson DJ and Aubin Y, (2017) Assessment of the structure of pegylated-recombinant protein therapeutics by the NMR fingerprint assay, Journal of Pharmaceutical and Biomedical Analysis 138:351-356. Journal of Pharmaceutical and Biomedical Analysis 141:229-233 Sauvé S, Gingras G and Aubin Y, (2017) NMR study of Mutations of Glycine-52 Catalytic Domain of Diphtheria Toxin: Implication for Conjugated Vaccines, Journal of Pharmaceutical and Biomedical doi: 10.1016/j.jpba.2017.11.056.īrinson RG, Ghasriani H, Hodgson DJ, Adams K, McEwen K, Freedberg DI, Chen K, Keire DA, Aubin Y, and Marino JP (2017) Application of 2D-NMR with Room Temperature NMR Probes for the Assessment of the Higher Order Structure of Filgrastim. (2018) Gramillin A and B: Cyclic Lipopeptides Identified as the Nonribosomal Biosynthetic Products of Fusarium graminearum. Journal of Pharmaceutical and Biomedical Analysis 163:144-152.īrinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, Gingras G, Ghasriani H, Aubin Y, Pierens GK, Jia X, Mobli M, Grant HG, Keizer DW, Schweimer K, Ståhle J, Göran Widmalm G, Zartler ER, Lawrence CW, Reardon PN, Cort JR, Xu P, Ni F, Yanaka S, Kato K, Parnham SR, Tsao D, Blomgren A, Rundlöf T, Trieloff N, Schmieder P, Ross A, Skidmore K, Chen K, Keire D, Freedberg DI, Suter-Stahel T, Wider G, Ilc G, Plavec J, Bradley SA, Baldisseri DM, Sforça ML, de Mattos Zeri AC, Wei JY, Szabo CM, Amezcua CA, Jordan JB, Wikström M (2019) Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics, MAbs, 11:94-105.doi:10.1080/19420862.2018.1544454īahadoor A, Brauer EK, Bosnich W, Schneiderman D, Johnston A, Aubin Y, Blackwell B, Melanson JE, Harris LJ. Hodgson DJ, Ghasriani H, Aubin Y (2019) Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.
Li C, Bhavaraju S, Thibeault MP, Melanson J, Blomgren A, Rundlöf T, Kilpatrick E, Swann CJ, Rudd T, Aubin Y, Grant K, Butt M, Shum W, Kerim T, Sherwin W, Nakagawa Y, Pavón S, Arrastia S, Weel T, Pola A, Chalasani D, Walfish S, Atouf F, (2019) Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocin, J Pharm Biomed Anal, 166:105-112
0 kommentar(er)
